D.E. Shaw & Co’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

D.E. Shaw & Co’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,932	Closed	-$729	–	5151
2022 Q4	$729	Hold	40,932	–	–	﹤0.01%	4801
2022 Q3	$3K	Hold	40,932	–	–	﹤0.01%	5078
2022 Q2	$3K	Hold	40,932	–	–	﹤0.01%	5263
2022 Q1	$8K	Hold	40,932	–	–	﹤0.01%	5434
2021 Q4	$22K	Hold	40,932	–	–	﹤0.01%	5292
2021 Q3	$24K	Buy	40,932 +28,432	+227%	+$19.1K	﹤0.01%	4884
2021 Q2	$10K	Buy	+12,500	New	+$7.59K	﹤0.01%	4718

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

D.E. Shaw & Co's IBER.WS Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 40,932 shares — an estimated $729 sold.

D.E. Shaw & Co first reported a position in IBER.WS in Q2 2021 and held it in 7 quarters. The position peaked at $24K in Q3 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

D.E. Shaw & Co reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
D.E. Shaw & Co sold 40,932 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $729.
D.E. Shaw & Co first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 7 quarters.
D.E. Shaw & Co's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $24K in Q3 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.